Details of the Drug Combinations

General Information of This Drug (ID: DM2JGQ3)

Drug Name

Trametinib DM2JGQ3

Synonyms

GSK 1120212; GSK-1120212; GSK1120212; JTP 74057; JTP-74057; Mekinist; Trametinib (GSK1120212); Trametinib (GSK1120212JTP 74057); Trametinib (MEK inhibitor); 33E86K87QN; A1-01871; AK174783; CHEBI:75998; UNII-33E86K87QN

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Approved	[1]
Metastatic melanoma	2E2Z	Approved	[2]
Middle East Respiratory Syndrome (MERS)	1D64	Investigative	[3]
Severe acute respiratory syndrome (SARS)	1D65	Investigative	[3]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

113 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Abexinostat + Trametinib	DCE8PR5	Abexinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
ABT-263 + Trametinib	DCE4EGP	ABT-263	Glioblastoma (Cell Line: JHH-136)	[5]
Artemisinin + Trametinib	DCCTRXK	Artemisinin	DD2 (Cell Line: DD2)	[4]
AS602868 + Trametinib	DCZ30IT	AS602868	Glioblastoma (Cell Line: JHH-136)	[4]
AZD8055 + Trametinib	DCAJRS9	AZD8055	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
AZD8055 + Trametinib	DCZQ41N	AZD8055	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
AZD8055 + Trametinib	DCL1OQV	AZD8055	Glioblastoma (Cell Line: JHH-136)	[4]
Belinostat + Trametinib	DCWJQTU	Belinostat	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[5]
Belinostat + Trametinib	DCIQSBG	Belinostat	Embryonal rhabdomyosarcoma (Cell Line: RD)	[5]
BGJ398 + Trametinib	DCK2VEK	BGJ398	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[5]
BGJ398 + Trametinib	DCXWIX9	BGJ398	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[5]
BGJ398 + Trametinib	DC0G6QD	BGJ398	Embryonal rhabdomyosarcoma (Cell Line: RD)	[5]
BIIB-021 + Trametinib	DCS17Z2	BIIB-021	Glioblastoma (Cell Line: JHH-136)	[4]
BMS-754807 + Trametinib	DC1JBLT	BMS-754807	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
BMS-754807 + Trametinib	DCR02WS	BMS-754807	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[4]
BMS-754807 + Trametinib	DC5574T	BMS-754807	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
BMS-754807 + Trametinib	DCWP86P	BMS-754807	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
Buparlisib + Trametinib	DC7JHAI	Buparlisib	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[5]
Buparlisib + Trametinib	DCBOJNT	Buparlisib	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[5]
Buparlisib + Trametinib	DCLVFQ1	Buparlisib	Embryonal rhabdomyosarcoma (Cell Line: RD)	[5]
CA4P + Trametinib	DCC4G7O	CA4P	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
CA4P + Trametinib	DCKM6F1	CA4P	Glioblastoma (Cell Line: JHH-136)	[4]
Calindol + Trametinib	DC0ZCGP	Calindol	DD2 (Cell Line: DD2)	[4]
Ceritinib + Trametinib	DCH0NN5	Ceritinib	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[5]
Ceritinib + Trametinib	DCF017N	Ceritinib	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[5]
Ceritinib + Trametinib	DC6LJTA	Ceritinib	Embryonal rhabdomyosarcoma (Cell Line: RD)	[5]
Cladribine + Trametinib	DCTS3Z4	Cladribine	Glioblastoma (Cell Line: JHH-136)	[4]
DZNep + Trametinib	DC5Q9M8	DZNep	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
E7820 + Trametinib	DCUMLIZ	E7820	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Everolimus + Trametinib	DCBBMNI	Everolimus	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[4]
Everolimus + Trametinib	DCUZG52	Everolimus	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
Everolimus + Trametinib	DC5EVSE	Everolimus	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
Flavopiridol + Trametinib	DCX9BN2	Flavopiridol	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
GDC-0068 + Trametinib	DCC2IXN	GDC-0068	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[4]
GDC-0068 + Trametinib	DCOGK5V	GDC-0068	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
GDC-0068 + Trametinib	DC8N0RG	GDC-0068	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
GDC-0084 + Trametinib	DCROZ8H	GDC-0084	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[5]
GDC-0084 + Trametinib	DCW5YT2	GDC-0084	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[5]
GDC-0084 + Trametinib	DC7CN1A	GDC-0084	Embryonal rhabdomyosarcoma (Cell Line: RD)	[5]
GDC-0980/RG7422 + Trametinib	DCLB79G	GDC-0980/RG7422	Glioblastoma (Cell Line: JHH-136)	[4]
GDC-0980/RG7422 + Trametinib	DCFTAZX	GDC-0980/RG7422	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[5]
GDC-0980/RG7422 + Trametinib	DCHE4QO	GDC-0980/RG7422	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[5]
GDC-0980/RG7422 + Trametinib	DCKCOWC	GDC-0980/RG7422	Embryonal rhabdomyosarcoma (Cell Line: RD)	[5]
GDC0941 + Trametinib	DC0OGBX	GDC0941	Glioblastoma (Cell Line: JHH-136)	[4]
GSK2126458 + Trametinib	DCBOW13	GSK2126458	Glioblastoma (Cell Line: JHH-136)	[4]
GSK2126458 + Trametinib	DCWCEJE	GSK2126458	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[5]
GSK2126458 + Trametinib	DCVCXRI	GSK2126458	Embryonal rhabdomyosarcoma (Cell Line: RD)	[5]
GSK690693 + Trametinib	DCTUUAQ	GSK690693	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[4]
GSK690693 + Trametinib	DCF0ZVQ	GSK690693	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
GSK690693 + Trametinib	DCQXD4J	GSK690693	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
JQ1 + Trametinib	DCQON09	JQ1	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[4]
JQ1 + Trametinib	DC3OV52	JQ1	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
JQ1 + Trametinib	DCGUSF6	JQ1	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
Lumefantrine + Trametinib	DCM7HDN	Lumefantrine	DD2 (Cell Line: DD2)	[4]
Mebendazole + Trametinib	DC95J9G	Mebendazole	Glioblastoma (Cell Line: JHH-136)	[4]
MK-2206 + Trametinib	DCLYGZ8	MK-2206	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[4]
MK-2206 + Trametinib	DCJ4851	MK-2206	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
MK-2206 + Trametinib	DCYKNNJ	MK-2206	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
Obatoclax + Trametinib	DCZXY5O	Obatoclax	Glioblastoma (Cell Line: JHH-136)	[5]
ONC201 + Trametinib	DC9WG4C	ONC201	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
OSI-027 + Trametinib	DCOT0BD	OSI-027	Glioblastoma (Cell Line: JHH-136)	[4]
PAC1 + Trametinib	DCNYFPL	PAC1	Glioblastoma (Cell Line: JHH-136)	[4]
Palbociclib + Trametinib	DCLWZOC	Palbociclib	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
Pelitinib + Trametinib	DC1EOE7	Pelitinib	Glioblastoma (Cell Line: JHH-136)	[4]
PF-04691502 + Trametinib	DCBFALZ	PF-04691502	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[4]
PF-04691502 + Trametinib	DC3WYUJ	PF-04691502	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
PF-04691502 + Trametinib	DCFH8KY	PF-04691502	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
PMID25656651-Compound-5 + Trametinib	DC3409A	PMID25656651-Compound-5	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[5]
PMID25656651-Compound-5 + Trametinib	DCS5BNF	PMID25656651-Compound-5	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[5]
PMID25656651-Compound-5 + Trametinib	DCVTL4W	PMID25656651-Compound-5	Embryonal rhabdomyosarcoma (Cell Line: RD)	[5]
RTB101 + Trametinib	DCI41AE	RTB101	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
RTB101 + Trametinib	DCMVQXP	RTB101	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[5]
RTB101 + Trametinib	DCZXVQJ	RTB101	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[5]
RTB101 + Trametinib	DCZNA62	RTB101	Embryonal rhabdomyosarcoma (Cell Line: RD)	[5]
Sapanisertib + Trametinib	DCDTHE4	Sapanisertib	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[5]
Sapanisertib + Trametinib	DC4CMRP	Sapanisertib	Embryonal rhabdomyosarcoma (Cell Line: RD)	[5]
SCH772984 + Trametinib	DCQF7KH	SCH772984	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[5]
SCH772984 + Trametinib	DCQWBN9	SCH772984	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[5]
TAK-733 + Trametinib	DCJGW4L	TAK-733	Glioblastoma (Cell Line: JHH-136)	[4]
Topetecan + Trametinib	DCO1OPG	Topetecan	Glioblastoma (Cell Line: JHH-136)	[4]
Trametinib + JQ1	DC5SX13	JQ1	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[5]
Trametinib + JQ1	DC0F9K2	JQ1	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Trametinib + Carfilzomib	DCSJAS3	Carfilzomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Trametinib + Panobinostat	DC5Y4RF	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Trametinib + Ym155	DCWNE8O	Ym155	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[5]
Trametinib + RTB101	DCHZOKA	RTB101	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Trametinib + Abexinostat	DCCGPAR	Abexinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Trametinib + CA4P	DCW6XU0	CA4P	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Trametinib + CUDC-101	DCHAQEW	CUDC-101	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[5]
Trametinib + Cantharidin	DCFH778	Cantharidin	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[5]
Trametinib + RAF265	DCYAO0L	RAF265	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[5]
Trametinib + Daporinad	DC3NWX3	Daporinad	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Trametinib + THAPSIGARGIN	DCMEWB8	THAPSIGARGIN	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[5]
Trametinib + SNS-032	DC380M8	SNS-032	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[5]
Trametinib + GDC-0980/RG7422	DC4JR8F	GDC-0980/RG7422	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[5]
Trametinib + SNDX-275	DCA2KUI	SNDX-275	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[5]
Trametinib + SNDX-275	DCTPW8M	SNDX-275	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Trametinib + Niclosamide	DCYIQL2	Niclosamide	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[5]
Trametinib + AS602868	DCMSVVY	AS602868	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[5]
Trametinib + Tamoxifen	DCAEXOU	Tamoxifen	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[5]
Trametinib + Ciclopirox	DC0G7ZZ	Ciclopirox	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[5]
Trametinib + Resminostat	DC8Y5HL	Resminostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Trametinib + BIIB-021	DCRC1YZ	BIIB-021	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[5]
Trametinib + BMS-754807	DC0T4P3	BMS-754807	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Trametinib + Prazosin	DC58PAT	Prazosin	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[5]
Trametinib + Mefloquine	DC8K9SY	Mefloquine	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[5]
Trametinib + Vinpocetine	DC7DCNY	Vinpocetine	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[5]
Trametinib + Auranofin	DCHMZEG	Auranofin	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[5]
Triciribine + Trametinib	DC3EVQJ	Triciribine	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[4]
Triciribine + Trametinib	DC40TFR	Triciribine	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
Triciribine + Trametinib	DCCVL5E	Triciribine	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
Verteporfin + Trametinib	DCLNU90	Verteporfin	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[5]
Verteporfin + Trametinib	DCMHQGZ	Verteporfin	Embryonal rhabdomyosarcoma (Cell Line: RD)	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 113 DrugCom(s)

33 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Buparlisib + Trametinib	DCR3LLR	Buparlisib	Advanced and Selected Solid Tumors	[6]
Ruxolitinib + Trametinib	DCGV0GY	Ruxolitinib	Colorectal Cancer	[7]
Trametinib + Gemcitabine	DC244C2	Gemcitabine	Cancer	[8]
Trametinib + Erlotinib	DCADB8C	Erlotinib	Cancer	[9]
Trametinib + Dabrafenib	DCEV54D	Dabrafenib	Cancer	[10]
Trametinib + Pazopanib	DCK3TSF	Pazopanib	Solid Tumors	[11]
Trametinib + Pemetrexed	DCTTELS	Pemetrexed	Cancer	[9]
Trametinib + Docetaxel	DCWYV9Y	Docetaxel	Cancer	[9]
Trametinib + Dabrafenib	DCGYK2H	Dabrafenib	Glioma	[12]
Trametinib + Dabrafenib	DCI71OM	Dabrafenib	Non-small-cell lung cancer	[13]
Trametinib + Nilotinib	DC82VD5	Nilotinib	Metastatic Melanoma	[14]
Trametinib + Dabrafenib	DCRRRIO	Dabrafenib	Melanoma	[15]
Trametinib + INCB039110	DCSFEUK	INCB039110	Melanoma	[16]
Trametinib + Digoxin	DCVO1IC	Digoxin	Melanoma	[17]
Trametinib + Phenformin	DCVX3FV	Phenformin	Melanoma	[18]
Trametinib + Metformin	DCXN8SO	Metformin	Melanoma	[19]
Trametinib + Capmatinib	DC0QVG2	Capmatinib	Metastatic Lung Non-Small Cell Carcinoma	[20]
Trametinib + LEE011	DC6HSDF	LEE011	Solid Tumors for Phase Ib	[21]
Trametinib + Alpelisib	DCDEX6L	Alpelisib	Meningioma	[22]
Trametinib + Everolimus	DCFMCMZ	Everolimus	Recurrent World Health Organization (WHO) Grade II Glioma	[23]
Trametinib + Ponatinib	DCGOTK3	Ponatinib	Non Small Cell Lung Cancer	[24]
Trametinib + Ceritinib	DCKQWQ1	Ceritinib	Non-small Cell Lung Cancer	[25]
Trametinib + HKI-272	DCNKNAH	HKI-272	Advanced Malignant Solid Neoplasm	[26]
Trametinib + Al3818	DCNXY1R	Al3818	Non Small Cell Lung Cancer	[27]
Trametinib + Lapatinib	DCOAJVZ	Lapatinib	Colorectal Cancer	[28]
Trametinib + EGF816	DCOFJW9	EGF816	EGFR-mutant Non-small Cell Lung Cancer	[29]
Trametinib + CO-1686	DCRLIJR	CO-1686	Non-small Cell Lung Cancer	[30]
Trametinib + Azacitidine	DCVV9AB	Azacitidine	Leukemia, Juvenile Myelomonocytic	[31]
Trametinib + Hydroxychloroquine	DCYLUD6	Hydroxychloroquine	Metastatic Pancreatic Carcinoma	[32]
Trametinib + Momelotinib	DCZMV46	Momelotinib	Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer	[33]
Trametinib + Degarelix	DCOI6AY	Degarelix	Prostate Cancer	[34]
Trametinib + Venetoclax	DCOYZ54	Venetoclax	Recurrent Acute Myeloid Leukemia	[35]
Trametinib + Pazopanib	DCG7XD7	Pazopanib	Gastrointestinal Stromal Tumors	[36]
------------------------------------------------------------------------------------


⏷ Show the Full List of 33 DrugCom(s)

1 Approved Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Trametinib + Dabrafenib	DCXQC9Q	Dabrafenib	Melanoma	[37]
------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6495).
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
4	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
6	ClinicalTrials.gov (NCT01155453) A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients
7	ClinicalTrials.gov (NCT04303403) Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma
8	ClinicalTrials.gov (NCT01231581) Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
9	ClinicalTrials.gov (NCT01192165) Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
10	ClinicalTrials.gov (NCT01336634) Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
11	ClinicalTrials.gov (NCT01438554) Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
12	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
13	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
14	ClinicalTrials.gov (NCT04903119) Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma
15	ClinicalTrials.gov (NCT03754179) Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma
16	ClinicalTrials.gov (NCT03272464) INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.
17	ClinicalTrials.gov (NCT02915666) A Clinical Trial of Patients With Melanoma
18	ClinicalTrials.gov (NCT03026517) Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma
19	ClinicalTrials.gov (NCT02143050) Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients
20	ClinicalTrials.gov (NCT05435846) Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation
21	ClinicalTrials.gov (NCT02703571) Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors
22	ClinicalTrials.gov (NCT03631953) Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas
23	ClinicalTrials.gov (NCT04485559) Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
24	ClinicalTrials.gov (NCT03704688) Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer
25	ClinicalTrials.gov (NCT03087448) Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
26	ClinicalTrials.gov (NCT03065387) Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
27	ClinicalTrials.gov (NCT04967079) Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients
28	ClinicalTrials.gov (NCT02230553) Lapatinib Plus Trametinib in KRAS Mutant NSCLC
29	ClinicalTrials.gov (NCT03333343) Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
30	ClinicalTrials.gov (NCT02580708) Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
31	ClinicalTrials.gov (NCT05849662) A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
32	ClinicalTrials.gov (NCT03825289) Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
33	ClinicalTrials.gov (NCT02258607) Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase
34	ClinicalTrials.gov (NCT01990196) Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
35	ClinicalTrials.gov (NCT04487106) Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
36	ClinicalTrials.gov (NCT02342600) SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)
37	Clinical pipeline report, company report or official report of novartis.